Roche gets boost from FDA in bid to expand uses for Actemra

ZURICH (Reuters) – The U.S. Food and Drug Administration has granted breakthrough status to Roche's rheumatoid arthritis medication Actemra for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine.
Original Article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.